Contact
Home
Sitemap
Careers
About Us
Corporate Overview
Executive Management
Board Of Directors
Scientific Advisory Board
Careers
Pipeline
Pipeline Overview
Azedra™
Onalta™
Solazed™
Trofex™
Zemiva™
Molecular Medicine
Molecular Medicine Overview
Targeted Radiotherapeutics
Molecular Imaging Pharmaceuticals
Proprietary Technologies
Scientific Presentations
Scientific Posters
Bibliography
In The Clinic
Clinical Trials Overview
Oncology Trials
Cardiovascular Trials
Patient Resources
Investor Center
Media Room
Media Room Overview
Press Releases
Glossary
Scientific Presentations
Scientific Posters
Bibliography
Media Room
Media Room Overview
Press Releases
Archive
Glossary
Scientific Presentations
Scientific Posters
Bibliography
Media Room
>>
Press Releases
Press Releases
2010
Date
Publication
07/16/10
Molecular Insight Receives Fifth Extension
07/14/10
Molecular Insight Pharmaceuticals’ Zemiva Phase 2 Data Published in Journal of the American College of Cardiology
07/05/10
Molecular Insight Receives Fourth Extension of Waiver Agreement with Bond Holders
06/25/10
Molecular Insight Pharmaceuticals Receives NASDAQ Notification Letter
06/23/10
Molecular Insight Pharmaceuticals Presents Positive Data from Azedra™ Phase 2a Clinical Trial in Neuroblastoma Tumors
06/22/10
Molecular Insight Receives Third Extension of Waiver Agreement with Bond holders
06/08/10
Molecular Insight Pharmaceuticals Presents Oncology Data at Society of Nuclear Medicine 2010 Annual Meeting
05/18/10
Molecular Insight Receives Second Extension of Waiver Agreement with Bond holders
05/06/10
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2010 Financial and Operational Results
04/27/10
Molecular Insight Pharmaceuticals Regains Compliance with NASDAQ Minimum Market Value Rule
04/16/10
Molecular Insight Receives 30-Day Extension of Waiver Agreement with Bond holders
04/12/10
Molecular Insight Pharmaceuticals’ Onalta Phase 2 Data Published in Journal of Clinical Oncology
03/22/10
Molecular Insight Pharmaceuticals Advances Solazed™ for Malignant Melanoma into Phase 1 Clinical Trial
03/16/10
Molecular Insight Pharmaceuticals, Inc. to Report Fourth Quarter and Year-End 2009 Financial and Operational Results Today
03/16/10
Molecular Insight Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial and Operational Results
03/15/10
Molecular Insight Pharmaceuticals Receives NASDAQ Notification Letter
01/27/10
Molecular Insight Announces Updates to Board of Directors
01/07/10
Molecular Insight Pharmaceuticals Announces Personnel Reduction to Align Operations with Development Activities
2009
Date
Publication
11/24/09
Molecular Insight Pharmaceuticals Announces Changes to Board
11/11/09
Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
11/09/09
Molecular Insight Pharmaceuticals Reports Third Quarter 2009 Financial Results
10/26/09
Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009
10/21/09
Molecular Insight Pharmaceuticals Finalizes Onalta™ Manufacturing and Supply Agreements
10/05/09
Molecular Insight Pharmaceuticals Presents Azedra™ 12-Month Efficacy Data from Phase I Clinical Trial in Neuroendocrine Tumors
09/04/09
Molecular Insight to Present at Rodman and Renshaw Healthcare Conference
09/02/09
Molecular Insight Pharmaceuticals, Inc. Sub-licenses Onalta™ For Development
08/28/09
Molecular Insight Pharmaceuticals Files Universal Shelf Registration Statement
08/11/09
Molecular Insight Pharmaceuticals Reports Inducement Grant for CEO Under NASDAQ Marketplace Rule 4350
08/10/09
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial and Operational Results
08/07/09
Molecular Insight Pharmaceuticals, Inc. Advances Azedra Program into Pivotal Phase 2 Therapeutic Trial in Neuroendocrine Cancer Patients
08/05/09
Molecular Insight Pharmaceuticals, Inc. Appoints Charles H. Abdalian, Jr., Vice President of Finance, CFO
06/16/09
Molecular Insight Pharmaceuticals, Inc. Presents Clinical Data on Prostate Cancer Diagnostic
06/10/09
Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the Society of Nuclear Medicine 2009 Annual Meeting
05/14/09
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed with Phase 3 Development of Onalta™
05/13/09
Molecular Insight Pharmaceuticals Expands Management Team by Appointing Daniel L. Peters as President and Chief Executive Officer
05/11/09
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2009 Financial and Operational Results
05/04/09
Molecular Insight Pharmaceuticals, Inc. to Announce First Quarter Financial Results on May 11, 2009
03/26/09
Molecular Insight Releases Positive, Detailed Phase 2 Trial Results Demonstrating Ability of Zemiva™ to Rapidly Detect Cardiac Ischemia
03/16/09
Molecular Insight Pharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial and Operational Results
03/11/09
Molecular Insight Receives Special Protocol Assessment Approval from FDA for Phase 2 Trial of Azedra™, a Radiotherapeutic to Treat Neuroendocrine Cancer
02/03/09
Molecular Insight Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference
02/02/09
Molecular Insight Pharmaceuticals Announces Board and Senior Management Appointments
01/05/09
Molecular Insight Pharmaceuticals Announces Resignation of Director
2008
Date
Publication
12/30/08
Publication in Journal of Medicinal Chemistry Highlights Molecular Insight Pharmaceuticals’ Program for Targeting Prostate Cancer
12/08/08
Molecular Insight Pharmaceuticals, Inc. to Present at 2008 RBC Capital Markets Healthcare Conference
11/13/08
Molecular Insight Pharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11/10/08
Molecular Insight Announces Positive Results from a Prospective Analysis of Phase 2b Data for Zemiva™ in Emergency Department Setting
11/07/08
Molecular Insight Pharmaceuticals, Inc. To Present Results from a Prospective Analysis of Zemiva™ Phase 2b Data at the 2008 Scientific Sessions of the American Heart Association
11/05/08
Molecular Insight Pharmaceuticals, Inc. to Present at Rodman and Renshaw 10th Annual Healthcare Conference
10/30/08
Molecular Insight Pharmaceuticals, Inc. To Announce Third Quarter Financial Results on November 13, 2008
10/21/08
Massachusetts General Hospital Cancer Center Receives 2-year Grant From Alex's Lemonade Stand Foundation
09/25/08
Molecular Insight Pharmaceuticals, Inc. Appoints John W. Babich, Ph.D., as Interim CEO and Chairman of the Board
09/22/08
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
09/22/08
Molecular Insight Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
08/27/08
Molecular Insight Pharmaceuticals, Inc. To Present at NewsMakers in the Biotech Industry Conference
08/13/08
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
07/30/08
Molecular Insight Pharmaceuticals, Inc. To Announce Second Quarter Financial Results on August 13, 2008
06/19/08
Molecular Insight Pharmaceuticals, Inc. To Present At Jefferies Healthcare Conference
06/18/08
Molecular Insight Pharmaceuticals, Inc. Presents Three Studies on Trofex™ Program for Prostate Cancer Diagnosis and Staging
06/18/08
Molecular Insight Pharmaceuticals, Inc. Reports Onalta™ Tissue Distribution Data Support Clinical Development Program
06/16/08
Molecular Insight Pharmaceuticals, Inc. Announces Additional Panel Participation at the BIO 2008 International Convention
06/16/08
Molecular Insight Pharmaceuticals, Inc. Reports Preclinical Data on Solazed™ for Treatment of Metastatic Melanoma at Society of Nuclear Medicine (SNM) Meeting
06/12/08
Molecular Insight Pharmaceuticals, Inc. Initiates Trofex™ Phase 1 Trial for the Detection and Staging of Metastatic Prostate Cancer
06/11/08
Molecular Insight Pharmaceuticals, Inc. Announces Panel Participation at the BIO 2008 International Convention
06/02/08
Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results of Azedra™ Phase I Trial in Neuroendocrine Cancer Patients at ASCO
05/20/08
Molecular Insight Pharmaceuticals, Inc. to Present Data on Four Oncology Candidates at Society of Nuclear Medicine 2008 Annual Meeting
05/16/08
Molecular Insight Pharmaceuticals, Inc. To Present Interim Phase 1 Data at ASCO on Azedra™ in Malignant Pheochromocytoma/Paraganglioma Patients
05/14/08
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
05/10/08
Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra™ Clinical Trial in Neuroblastoma Patients
05/05/08
Molecular Insight Pharmaceuticals, Inc. To Announce First Quarter Financial Results on May 14, 2008
03/31/08
Molecular Insight Pharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial and Operational Results
03/12/08
Molecular Insight Pharmaceuticals, Inc. to Announce Fourth Quarter and Year-End Financial Results on March 31, 2008
02/06/08
Molecular Insight Pharmaceuticals, Inc. To Present at BIO CEO & Investor Conference
01/23/08
Molecular Insight Pharmaceuticals, Inc. To Present at Wachovia 2008 Healthcare Conference
01/22/08
Molecular Insight Pharmaceuticals, Inc. to Host Analyst Day Event and Webcast February 5, 2008
2007
Date
Publication
11/12/07
Molecular Insight Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11/09/07
Molecular Insight Pharmaceuticals, Inc. Prices $150 Million Bond Financing
11/05/07
Molecular Insight Pharmaceuticals, Inc. To Announce Third Quarter Financial Results On November 12, 2007
10/25/07
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical TrofexTM Prostate Cancer Data at AACR
10/18/07
Molecular Insight Pharmaceuticals, Inc. Announces Positive Results of AzedraTM Phase 1 Dosimetry Trial for Neuroendocrine Tumors
10/03/07
Molecular Insight Pharmaceuticals, Inc. Completes Strategic Purchase of Radiopharmaceutical Manufacturing Facility
09/19/07
Molecular Insight Pharmaceuticals, Inc. To Present at 2007 UBS Global Life Sciences Conference
09/11/07
Molecular Insight Pharmaceuticals, Inc. to Host Conference Call to Review Positive ZemivaTM Phase 2b Data Presented at ASNC
09/10/07
Molecular Insight Pharmaceuticals, Inc. Announces Positive Results of Pilot Investigation of ZemivaTM in Emergency Department Setting
09/07/07
ZemivaTM Normals Database From Molecular Insight Pharmaceuticals, Inc. Enables Accurate Determination of Abnormal Heart Activity
08/29/07
Molecular Insight Pharmaceuticals, Inc. To Present At NewsMakers In The Biotech Industry Conference
08/21/07
Former FDA Deputy Commissioner Scott Gottlieb, M.D. joins Molecular Insight Pharmaceuticals, Inc. Board of Directors
08/16/07
Molecular Insight Pharmaceuticals, Inc. Announces Appointment of Donald E. Wallroth as Chief Financial Officer
08/13/07
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results
08/06/07
Molecular Insight Pharmaceuticals, Inc. Selected to Present Zemiva™ Phase 2b Clinical Trial Data in Late Breaking Clinical Forum at American Society of Nuclear Cardiology Annual Meeting
08/06/07
Molecular Insight Pharmaceuticals, Inc. To Announce Second Quarter Financial Results On August 13, 2007
06/25/07
Molecular Insight Pharmaceuticals, Inc. Initiates First of Two Planned Pivotal Registration Trials for Zemiva™ in Detection of Cardiac Ischemia
06/20/07
Molecular Insight Pharmaceuticals, Inc. To Present At Jefferies Healthcare Conference
06/04/07
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
06/04/07
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
05/17/07
Molecular Insight Pharmaceuticals, Inc. Enters into Agreement to Purchase Radiopharmaceutical Manufacturing Facility
05/15/07
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2007 Financial Results
05/10/07
Molecular Insight Pharmaceuticals, Inc. Initiates Azedra™ Therapeutic Trial in Neuroendocrine Cancer Patients
05/09/07
Molecular Insight Pharmaceuticals, Inc. to Host Conference Call on May 15
05/01/07
Molecular Insight Pharmaceuticals, Inc. Announces Participation in Sessions at BIO 2007 International Convention